BioSante issued new LibiGel method of use patent

BioSante Pharmaceuticals (NASDAQ: BPAX) has been granted a new U.S. patent covering the method of use of its LibiGel  testosterone gel for treating female sexual dysfunction (FSD) and hypoactive sexual desire disorder (HSDD).

The patent covers methods for treating FSD and HSDD and also includes using a metered dosage device to deliver the defined dose of the testosterone formulation in LibiGel.

“The patent protects the use of LibiGel in treating FSD and HSDD, and the bottle we used in our clinical work, as well as in the intended commercial product, and extends our patent protection to the end of 2028,” CEO Stephen Simes said in a statement. “Our objective has been to continue to strengthen our intellectual property covering LibiGel and this patent is a major achievement in that direction,” he added.